Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:124:61-79.

Cryptococcal infections in non-HIV-infected patients

Affiliations

Cryptococcal infections in non-HIV-infected patients

Peter G Pappas. Trans Am Clin Climatol Assoc. 2013.

Abstract

Infections due to Cryptococcus species occur globally and in a wide variety of hosts, ranging from those who are severely immunosuppressed to those who have phenotypically "normal" immune systems. Approximately 1 million cases of cryptococcosis occur throughout the world, and is it estimated that there are 650,000 associated deaths annually. Most of these cases occur among patients with advanced HIV disease, but a growing number occur among solid organ transplant recipients and others receiving exogenous immunosuppression, patients with innate and acquired immunodeficiency, and otherwise immunologically normal hosts. Much of our recent knowledge is solely derived from clinical experience over the last 2 to 3 decades of cryptococcosis among HIV-infected patients. However, based on recent observations, it is clear that there are substantial differences in the epidemiology, clinical features, approaches to therapy, and outcome when comparing HIV-infected to non-HIV-infected individuals who have cryptococcosis. If one carefully examines cryptococcosis in the three largest subgroups of patients based on host immune status, specifically, those with HIV, solid organ transplant recipients, and those who are non-HIV, non-transplant (NHNT) infected persons, then one can observe very different risks for infection, varied clinical presentations, long-term complications, mortality, and approaches to therapy. This article focuses on cryptococcosis in the non-HIV-infected patient, including a brief review of ongoing events in the Pacific Northwest of the United States and Canada relative to the outbreak of Cryptococcus gattii infections among a largely immunologically normal population, and highlights some of the key insights and questions which have emerged as a result of these important new observations.

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest: None disclosed.

Figures

Fig. 1.
Fig. 1.
Differential site of infection by host immune status among 302 patients with cryptococcosis at UAB, 1996–2010. (Abbreviations: HIV, human immunodeficiency virus; OTRs, organ transplant recipients; NHNT, non-HIV, non-transplant; CNS, central nervous system.)

References

    1. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30. - PubMed
    1. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33(5):690–9. - PubMed
    1. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE. 2008;3:1–9. - PMC - PubMed
    1. Singh N, Husain S, De Vera M, et al. Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore) 2004;83(3):188–92. - PubMed
    1. Singh N, Forrest G AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplant recipients. Am J Transplant. 2009;9(suppl 4):S192–8. - PubMed

LinkOut - more resources